Using Nonclassical Estrogen Signaling to Prevent Melanoma
Using Nonclassical Estrogen Signaling to Prevent Melanoma
批准号:
9895651
负责人:
TODD W RIDKY
金额:
$44.28万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2024-03-31
关键词:
AKAP12 geneAgonistCessation of lifeCyclic AMPCyclic AMP-Dependent Protein KinasesDNA DamageDNA RepairDNA Sequence AlterationDataDevelopmentDiagnosisDiseaseDrug TargetingEnzymesEpigenetic ProcessEstradiolEstrogen Nuclear ReceptorEstrogen Receptor alphaEstrogen ReceptorsEstrogen receptor positiveEstrogensExposure toFamily history ofFemaleFutureG-Protein-Coupled ReceptorsGTP-Binding ProteinsGenderGeneticGenetic TranscriptionGenetically Engineered MouseGenome StabilityGrowthHairHealthHistone AcetylationHistone DeacetylaseHistone Deacetylase InhibitorHistonesHumanImmunofluorescence ImmunologicImmunotherapyIn VitroIncidenceLigandsLightMalignant - descriptorMass Spectrum AnalysisMediatingMedicalMemoryMetastatic MelanomaModelingMusMutagenesisMutationNucleotide Excision RepairOncogenicOutcomePathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhosphorylationPhysiologicalPregnancyPrevention strategyProteinsReceptor ActivationReceptor SignalingRiskSignal TransductionSiteSkinSkin CancerSkin PigmentationSomatic MutationSouthwestern BlottingSun ExposureSurgical incisionsTestingTransferaseUV Radiation ExposureUV induced DNA damageWithdrawalWorkXPA geneadvanced diseasecancer celleffective therapyepigenetic memoryestrogen receptor gammaestrophilinexome sequencingexperimental studyhigh riskhistone acetyltransferaseimprovedin vivomalemelanocytemelanomamennovel therapeuticspreventprotective effectrecruitresponsesexskin xenografttargeted treatmenttherapeutic targettumortumor progressionultraviolet
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary: Despite advances in melanoma treatment, only 33% of patients with advanced
disease respond to the most effective therapy and mean survival is only 23 months. Millions of people
with red hair, or light skin pigmentation have an especially high melanoma risk. Although strategies to
decrease this risk are lacking, our recent discoveries suggest that melanoma incidence may be
diminished by pharmacologically activating the G-Protein Estrogen Receptor (GPER), a protein on
melanocytes with activity completely distinct from the classic estrogen receptor (ERα/β). Although there
are no approved drugs that target GPER, GPER is activated in melanocytes by a selective synthetic
compound (G-1) that does not have any classic estrogen activity. We recently determined that
pharmacologic GPER activation in vivo inhibits established melanomas, largely by inducing terminal
differentiation in cancer cells. Our preliminary studies now suggest that G-1 mediated GPER activation
in melanocytes induces long-term epigenetic changes that prevent future melanoma, while allowing
skin melanocytes to continue to function normally.
In Aim I we will use primary human melanocytes to determine the specific histone modifying enzymes
required for inducing epigenetic transcriptional memory that maintains a heightened state of cellular
differentiation after transient GPER activation, and test whether HDAC inhibition potentiates the
differentiation effects of the GPER agonist.
In Aim II we will validate preliminary results suggesting that GPER signaling induces pathways that
promote DNA repair, and thereby minimizes the accumulation of DNA mutations after ultraviolet (UV)
exposure. We will determine the mechanism(s) downstream of GPER that mediate the improved DNA
damage response, which may help highlight additional therapeutic targets.
In Aim III we will use both human and mouse melanoma models to directly test whether G-1
activation of GPER promotes DNA repair after UV exposure in vivo, and inhibits melanoma
development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of Endogenous DOPA Signaling on Melanocyte Homeostasis and Melanoma Susceptibility
-
批准号:10475365
-
项目类别:
-
资助金额:$35.75万
-
财政年份:2021
-
负责人:TODD W RIDKY
-
依托单位:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
-
批准号:10112838
-
项目类别:
-
资助金额:$43.9万
-
财政年份:2019
-
负责人:TODD W RIDKY
-
依托单位:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
-
批准号:10580032
-
项目类别:
-
资助金额:$41.94万
-
财政年份:2019
-
负责人:TODD W RIDKY
-
依托单位:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
-
批准号:10381619
-
项目类别:
-
资助金额:$42.42万
-
财政年份:2019
-
负责人:TODD W RIDKY
-
依托单位:
Signaling Modulators in Epidermal Carcinogenesis
-
批准号:8683127
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2012
-
负责人:TODD W RIDKY
-
依托单位:
Signaling Modulators in Epidermal Carcinogenesis
-
批准号:8539749
-
项目类别:
-
资助金额:$31.21万
-
财政年份:2012
-
负责人:TODD W RIDKY
-
依托单位:
Signaling Modulators in Epidermal Carcinogenesis
-
批准号:8219454
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2012
-
负责人:TODD W RIDKY
-
依托单位:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
-
批准号:8131855
-
项目类别:
-
资助金额:$11.95万
-
财政年份:2007
-
负责人:TODD W RIDKY
-
依托单位:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
-
批准号:7495164
-
项目类别:
-
资助金额:$11.95万
-
财政年份:2007
-
负责人:TODD W RIDKY
-
依托单位:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
-
批准号:7664424
-
项目类别:
-
资助金额:$11.95万
-
财政年份:2007
-
负责人:TODD W RIDKY
-
依托单位:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
-
批准号:7926955
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2007
-
负责人:TODD W RIDKY
-
依托单位:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
-
批准号:7210929
-
项目类别:
-
资助金额:$11.95万
-
财政年份:2007
-
负责人:TODD W RIDKY
-
依托单位:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
-
批准号:8188582
-
项目类别:
-
资助金额:$11.85万
-
财政年份:2007
-
负责人:TODD W RIDKY
-
依托单位:
Ras Dependent Human Cutaneous Neoplasia
-
批准号:6917268
-
项目类别:
-
资助金额:$5.75万
-
财政年份:2003
-
负责人:TODD W RIDKY
-
依托单位:
Ras Dependent Human Cutaneous Neoplasia
-
批准号:6803961
-
项目类别:
-
资助金额:$5.44万
-
财政年份:2003
-
负责人:TODD W RIDKY
-
依托单位:
Ras Dependent Human Cutaneous Neoplasia
-
批准号:6587898
-
项目类别:
-
资助金额:$5.19万
-
财政年份:2003
-
负责人:TODD W RIDKY
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: